A phase III randomised study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumour responding to Imatinib mesylate.
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 21 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Nov 2011 UKCRN reports the trial status is completed, and actual end date is 11 Mar 2011.
- 27 May 2010 Additional trial locations (Australia, France, Germany, Netherlands, New Zealand, Spain) added as reported by ISRCTN: Current Controlled Trials record.